SCHEMBL23218211

SCHEMBL23218211

CC(C)c1oc2ccc(Br)cc2c1CO

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 1/20 0.42
PIM1 P11309 2/20 0.41
CA12 O43570 3/20 0.39
CA9 Q16790 3/20 0.39
CASP6 P55212 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
NPC1 O15118 2/20 0.38
RAB9A P51151 2/20 0.38
GABRP O00591 1/20 0.37
GABRD O14764 1/20 0.37
GABRA1 P14867 1/20 0.37
GABRB1 P18505 1/20 0.37
GABRG2 P18507 1/20 0.37
GABRB3 P28472 1/20 0.37
GABRA5 P31644 1/20 0.37
GABRA3 P34903 1/20 0.37
GABRA2 P47869 1/20 0.37
GABRB2 P47870 1/20 0.37
GABRA4 P48169 1/20 0.37
GABRE P78334 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29853267 1.00 KCNH2 (0.42) KCNH2PIM1CA12CA9CASP6
SCHEMBL12248488 0.81 CASP6 (0.44) KCNH2PIM1CA12CA9CASP6
SCHEMBL29853136 0.80 KCNH2 (0.47) KCNH2PIM1CA12CA9CASP6
SCHEMBL23218435 0.80 KCNH2 (0.47) KCNH2PIM1CA12CA9CASP6
SCHEMBL23218349 0.78 PIM1 (0.49) KCNH2PIM1CA12CA9CASP6
SCHEMBL23218086 0.77 PIM1 (0.45) KCNH2PIM1CA12CA9CASP6
SCHEMBL29852587 0.77 PIM1 (0.45) KCNH2PIM1CA12CA9CASP6
SCHEMBL12248498 0.77 MAPT (0.46) PIM1CA12CA9CASP6NPC1
SCHEMBL23218877 0.76 KCNH2 (0.41) KCNH2PIM1CA12CA9CASP6
SCHEMBL23218189 0.75 PIM1 (0.43) KCNH2PIM1CA12CA9CASP6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12558341-B2 Oral complement factor D inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2026-02-24 US disclosed
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-06-12 US disclosed
EP-4041238-A1 ORAL COMPLEMENT FACTOR D INHIBITORS Biocryst Pharmaceuticals, Inc. (US) 2022-08-17 EP disclosed
CN-114502168-A Oral complement factor D inhibitors 拜奥克里斯特制药公司 2022-05-13 CN disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12558341-B2 Oral complement factor D inhibitors CFD, CFH, CFB KCNH2 839/4885PIM1 4538/4885CA12 1610/4885
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB KCNH2 4027/4885PIM1 4497/4885CA12 4035/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.